Table 2.

Increased snf⁺ dose affects neither sex determination nor dosage compensation activities of a Sxl cDNA expression construct

P(snf+) dose	Phenotype of Sxl−/Y; P(hsp70:SxlcF1) tra+/tra− partially feminized males*
	Viability relative to XY siblings with no P(hsp70:Sxl), (n siblings)	Sexual phenotype, n = 25; ±SEM
		Foreleg, percent intersex (n male sexcomb teeth)	Terminalia		Abdominal bristle number, male = 0			Pigmentation of hemitergites 5 and 6, percent all female (percent intersex)
			Anus, percent all female (percent intersex)	Genitalia, percent all female (percent intersex)	(percent relative to pseudofemale control†)
					7th hemitergite	6th hemisternite	7th hemisternite
0 (class A)	30%	100%	0%	0%	10.6  ±  0.4	7.9  ±  0.1	3.0  ±  0.1	86%
	(90)	(1.6  ±  0.2)	(100%)	(100%)	(45%)	(92%)	(58%)	(14%)
3 (class B)	36%	100%	12%	8%	9.6  ±  0.5	8.3  ±  0.2	3.1  ±  0.2	91%
	(105)	(1.5  ±  0.2)	(88%)	(92%)	(41%)	(96%)	(61%)	(9%)

^*From the cross: y w cm Sxl^f1ct⁶sn³/Binsinscy, y w sn B; TM3,Ser P{hsp70:SxlcF1 w^+mC}19/+ ☿☿ × ♂♂ w/Y; P{snf⁺w^+mC}P{snf⁺w^+mC} tra¹ P{snf⁺w^+mC}/tra¹. The reduced dose of tra⁺ moderated the otherwise overly strong feminizing effect of hsp70:SxlcF1. 

^† Pseudofemales were tra¹/tra¹ males (XY) feminized by a transgene constitutively expressing female-specific tra⁺ product.